BioIntelliSense company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biointellisense.com

Founded Year

2018

Stage

Series B | Alive

Total Raised

$84.8M

Last Raised

$45M | 1 yr ago

About BioIntelliSense

BioIntelliSense is developing a data service for continuous health monitoring, predictive analytics, and algorithmic clinical insights.

BioIntelliSense Headquarter Location

17301 W. Colfax Avenue Suite 152

Golden, Colorado, 80401,

United States

(888) 908-8804

ESPs containing BioIntelliSense

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers

These companies facilitate the electronic collection and transmission of patient data outside of a healthcare setting. Solutions include wearable devices as well as software and services that can often be tailored to specific conditions, such as diabetes, congestive heart failure, and hypertension.

BioIntelliSense named as Leader among 12 other companies, including Glooko, Huma, and TytoCare.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Medical Devices

In medicine, wirelessly-connected devices can include small, portable exam tools, wearable ambulatory monitors, and large immobile pieces of medical equipment. Embedded sensors can collect data related to patient health as well as device use and performance.

BioIntelliSense named as Highflier among 9 other companies, including Glooko, TytoCare, and AliveCor.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Biopharmaceuticals

These companies enable the capture and transmission of patient data outside of a healthcare setting. Solutions in this market include devices and/or patient engagement software that can be tailored to the specific clinical trial.

BioIntelliSense named as Leader among 6 other companies, including AliveCor, Huma, and Current Health.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing BioIntelliSense

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BioIntelliSense in 4 CB Insights research briefs, most recently on Apr 13, 2021.

Expert Collections containing BioIntelliSense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioIntelliSense is included in 12 Expert Collections, including Clinical Trials Tech.

C

Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

V

Value-Based Care & Population Health

1,049 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

11,620 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,861 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Conference Exhibitors

5,302 items

D

Digital Health 150

300 items

The winners of the second annual CB Insights Digital Health 150.

BioIntelliSense Patents

BioIntelliSense has filed 10 patents.

The 3 most popular patent topics include:

  • Biometrics
  • Computer buses
  • Serial buses
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/20/2019

5/3/2022

Graphical projections, Bearings (mechanical), Technical drawing, Roadsters, Light machine guns

Grant

Application Date

5/20/2019

Grant Date

5/3/2022

Title

Related Topics

Graphical projections, Bearings (mechanical), Technical drawing, Roadsters, Light machine guns

Status

Grant

Latest BioIntelliSense News

13:30 EDT Condition Monitoring Device Market to Surpass US$ 1,940.8 Million by 2030 - Coherent Market Insights

Jun 15, 2022

News provided by Share this article Share this article SEATTLE, June 15, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global condition monitoring device market is estimated to be valued at US$ 1,089.4 Million in 2022 and expected to exhibit a CAGR of 7.5% during the forecast period (2022-2030). Key Trends and Analysis of the Global Condition Monitoring Device Market: Key market players are collaborating to develop new patient monitoring devices for enabling remote patient monitoring, which is expected to propel the market growth over the forecast period. For instance, in July 2020, Philips, a health technology company, entered into a collaboration with BioIntelliSense a continuous health monitoring device manufacturer, for integrating BioIntelliSense's BioSticker medical device into Philips' remote patient monitoring (RPM) device that helps in monitoring chronic or complex conditions at home. Request Sample Copy of this Report at https://www.coherentmarketinsights.com/insight/request-sample/4938 Key Market Takeaways: The global condition monitoring device market is expected to exhibit a CAGR of 7.5% during the forecast period, owing to the growing prevalence of chronic conditions such as diabetes. For instance, according to the National Diabetes Statistics Report published in 2020, 34.2 million people in the U.S. had diabetes and around 26.9 million people were diagnosed with diabetes in 2018. Among product type, the pulse oximeters segment is expected to witness the highest growth in the global condition monitoring device market  over the forecast period. Technological advancement in oximeters is likely to promote the market growth over the forecast period. For instance, in August 2021, an engineering student from Mar Baselios College of Engineering and Technology, India developed OxiFine, a smart pulse oximeter that is easy to integrate with any smartphone application and cost-effective. The device can monitor pulse rate in beats per minute (BPM) and SpO2 level in percentage using the companion mobile application. In terms of application, the cold chain logistics segment is expected to witness the highest growth in the global condition monitoring device market over the forecast period. The segment growth can be attributed to the increasing development of biologics. For instance, in July 2020, Biocon Ltd, an innovation-led global biopharmaceuticals company, received funding of US$ 30 million from Tata Capital a private equity fund for the development of biologics. Key players operating in the global condition monitoring device market include General Electric Company, Koninklijke Philips N.V., Nihon Kohden Corporation, Hoffmann-La Roche Ltd, Braun Melsungen AG, Abbott, Masimo, Smiths Medical, 1byone, Inc., B Medical Systems, IndoSurgicals Pvt. Ltd., Biomedhelix (Pty) Ltd., and Thermofisher Scientific Inc. Request for Customization at https://www.coherentmarketinsights.com/insight/request-customization/4938 Detailed Segmentation: Blood Pressure Monitors Patient Monitoring Hospitals North America Buy this Complete Report Now at https://www.coherentmarketinsights.com/insight/buy-now/4938 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us:

BioIntelliSense Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioIntelliSense Rank

  • When was BioIntelliSense founded?

    BioIntelliSense was founded in 2018.

  • Where is BioIntelliSense's headquarters?

    BioIntelliSense's headquarters is located at 17301 W. Colfax Avenue, Golden.

  • What is BioIntelliSense's latest funding round?

    BioIntelliSense's latest funding round is Series B.

  • How much did BioIntelliSense raise?

    BioIntelliSense raised a total of $84.8M.

  • Who are the investors of BioIntelliSense?

    Investors of BioIntelliSense include Chicago Pacific Founders, UC Health, 7wire Ventures, Fresenius Medical Care, TripleTree and 10 more.

  • Who are BioIntelliSense's competitors?

    Competitors of BioIntelliSense include XCO and 3 more.

You May Also Like

VitalConnect Logo
VitalConnect

VitalConnect currently markets the VitalConnect Platform that includes two wearable biosensors combined with mobile and cloud-based software and analytics. HealthPatch MD and VitalPatch biosensors are wireless, adhesive patches that continuously monitor and record single-lead ECG, heart rate, heart rate variability, respiratory rate, skin temperature, posture, step count, and fall detection with clinical accuracy. Through the VitalConnect Platform, care teams receive accurate data and notifications to make health decisions and enable timely interventions.

Valencell Logo
Valencell

Valencell develops performance biometric sensor technology and licenses this patent-protected technology to consumer electronics manufacturers, mobile device and accessory makers, sports and fitness brands and gaming companies for integration into their products. Valencell's PerformTek biometric sensor technology employs active signal characterization to actively characterize biophysical signals for removing physical noise and extracting highly accurate biometric information.

N
Night Train

Night Train provides a sleep cycle monitoring and analysis solution. Night Train measures the distal skin temperature which correlates with normal melatonin production.

N
NanoVation

NanoVation provides respiratory monitoring solutions by offering a wireless wearable device that allows for noninvasive monitoring.

Validic Logo
Validic

Motivation Science is the developer of Validic, a digital health platform that provides a simple connection to secure, standardized data from specialized digital health technologies, such as wellness applications, wearables, fitness equipment and clinical devices.

C
Cadence

Cadence offers a remote care management platform that enables clinicians to monitor patient vitals remotely, provide personalized feedback via text message after each reading, and conduct one-on-one telehealth visits when needed.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.